Co-administration of an antacid containing aluminium and magnesium hydroxide (20 ml single dose) and doravirine (100 mg single dose) increased doravirine AUC and C24 by 1% and 3%, but decreased Cmax by 14%. No dose adjustment is required.

No clinically significant change in doravirine concentration was observed when an aluminum hydroxide/magnesium hydroxide/simethicone containing antacid was co-administered with doravirine.

Co-administration of doravirine (100 mg single dose) was studied with a single dose of an antacid suspension (1600 mg each aluminium hydroxide and magnesium hydroxide, and 160 mg of simethicone) was studied in13 subjects. Doravirine Cmax decreased by 14% and AUC and C24 increased by 1% and 3%, respectively. The authors conclude co-administration did not have a clinically relevant effect of doravirine pharmacokinetics.